GAMMA Investing LLC Boosts Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

GAMMA Investing LLC grew its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 3,595.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,353 shares of the life sciences company's stock after acquiring an additional 22,721 shares during the quarter. GAMMA Investing LLC's holdings in Integra LifeSciences were worth $5,140,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Integra LifeSciences during the 4th quarter valued at approximately $1,721,000. Paradigm Capital Management Inc. NY increased its stake in shares of Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after buying an additional 901,600 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Integra LifeSciences by 16.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 198,642 shares of the life sciences company's stock worth $4,505,000 after buying an additional 28,457 shares during the period. Woodline Partners LP acquired a new position in Integra LifeSciences in the fourth quarter valued at approximately $2,512,000. Finally, Soleus Capital Management L.P. acquired a new position in Integra LifeSciences in the fourth quarter valued at approximately $28,940,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IART. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. JPMorgan Chase & Co. reduced their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Finally, JMP Securities dropped their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to MarketBeat, Integra LifeSciences has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Trading Down 4.2%

Shares of Integra LifeSciences stock traded down $0.53 on Friday, hitting $12.16. The stock had a trading volume of 954,244 shares, compared to its average volume of 1,045,717. The stock has a 50 day moving average of $14.50 and a 200 day moving average of $20.24. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm has a market capitalization of $944.98 million, a P/E ratio of -135.10, a PEG ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same period last year, the business earned $0.55 EPS. The business's quarterly revenue was up 3.7% compared to the same quarter last year. Sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.